Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Korosho Asks Makers to Report Errors in Standard Product Code
March 5, 2001
- Roche CEO Expects Leadership from Mr Ogawa
March 5, 2001
- Nippon Shinyaku to Terminate Development of NS-49
March 5, 2001
- JPMA Compiles Report on Globalization
March 5, 2001
- Nippon Shinyaku, SSP to Codevelop Synthetic Steroid
March 5, 2001
- Drug Wholesaler Tie-ups, M&As in 2000
March 5, 2001
- Only 70% of Hospitals Hire No. of Drs Required by Law
March 5, 2001
- SAS Institute to Start New Portal Service for R&D
March 5, 2001
- COX2 Inhibitor Expected to Prevent NSAID-induced Ulcers: Pharmacia Forum
March 5, 2001
- AstraZeneca to Launch 3 New Drugs per Year in All Major Markets
March 5, 2001
- Large Intervention Study on Hypertension Targets 9,000 Patients in Japan
March 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 5, 2001
- Korosho to Deal with Biologics in Earnest
March 5, 2001
- Korosho to Issue GL Regarding NAT for HBV, HCV, HIV
March 5, 2001
- JPMA Invites Participation in Protein Structure Analysis Consortium
March 5, 2001
- 39 New Drugs Approved in 2000: PMSB
March 5, 2001
- Individual Health Insurance Cards to Be Introduced in April
March 5, 2001
- JPMA Calls For Maintenance of NHI Price Listing by Brand Name
March 5, 2001
- GL for Investigational Use of ES Cells Proposed
March 5, 2001
- Kemporen Proposes Series of Measures to Contain Medical Spending
March 5, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…